RadNet Reports Third Quarter Financial Results and Reaffirms Previously Announced 2016 Guidance Levels

• Total Net Revenue increased 7.8% to $224.6 million in the third quarter of 2016 from $208.4 million in the third quarter of 2015
  
  
• Adjusted EBITDA⁽¹⁾ increased 1.6% to $35.9 million in the third quarter of 2016 from $35.3 million in the third quarter of 2015 
  
  
• Earnings Per Share adjusted for unusual events taken place in the quarters (“Adjusted Earnings Per Share”) is $0.11 per share in the third quarter of 2016 as compared with  $0.10 from the third quarter of 2015
  
  
• Aggregate procedural volumes increased 6.7%; same center revenue increase 0.4% and same center procedural volumes increased 0.1%
  
  
• Completed a successful refinancing transaction during the quarter, extending debt maturities, increasing financial flexibility and eliminating concerns over access to capital for the near future

LOS ANGELES, Nov. 09, 2016 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 306 owned and/or operated outpatient imaging centers, today reported financial results for its third quarter of 2016.

Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, “I am pleased with our results and the progress we made this quarter. As compared with last year’s third quarter, our business demonstrated Revenue and EBITDA growth as well as positive same center revenue and procedural increases.  This is the tenth quarter in a row where we’ve experienced same center procedural growth, our industry’s best indicator of organic expansion.  Additionally, sequentially from our first and second quarters of this year, we have been able to methodically improve our Revenue and EBITDA performance.  This improvement is an indication, in a year where we completed no material acquisitions, that our focus on operational excellence is paying dividends.”  

Dr. Berger continued, “We continue to pursue several new health system partnerships on the west coast, a business model that has traditionally been a strength of our east coast operations, and we are looking to expand existing joint ventures on the east coast.  We are also aggressively pursuing network contracting and capitation opportunities on the east coast.  Furthermore, we are in the process of expanding our Breastlink breast disease management capabilities to our east coast markets.  We are optimistic about the progress we are making on these fronts and expect to be in a position later this year or early next year to announce the successful completion some of these initiatives.

“On July 1^st, we completed a refinancing transaction of our senior secured first lien term loan and revolving credit facility.  The transaction extends the maturity of these facilities to 2021 and increases our financial flexibility.  The refinancing also affords us the ability to continue to grow our business without having concerns about near term maturities and uncertainty around access to capital over the coming several years.”

Third Quarter Financial Results

For the third quarter of 2016, RadNet reported Revenue of $224.6 million, Adjusted EBITDA⁽¹⁾ of $35.9 million and Net Income of $1.6 million, respectively.  Revenue increased $16.3 million (or 7.8%), Adjusted EBITDA⁽¹⁾ increased $557,000 (or 1.6%) and Net Income decreased $6.3 million, respectively, over the third quarter of 2015.  Per share Net Income for the third quarter was $0.04, compared to per share Net Income in the third quarter of 2015 of $0.18 (based upon a weighted average number of diluted shares outstanding of 46.3 million and 44.8 million for these periods in 2016 and 2015, respectively).

The comparison of Net Income is affected by certain unusual items which occurred in each of the third quarters of 2016 and 2015.  During the third quarter of 2016, we wrote-off $709,000 of deferred financing fees and expensed $606,000 of one-time rating agency and legal fees related to our refinancing transaction completed on July 1, 2016.  We also had a one-time $1.2 million adjustment to depreciation expense and $2.0 million of severance related to our NY acquisitions.  Affecting the third quarter of 2015, we recorded a $4.8 million gain from the sale of our New Jersey facilities to our joint venture with Barnabas Health and $2.0 million of implementation revenue from the commencement of operations of our management service contract in Qatar.  Adjusting for these events in both quarters, Adjusted Earnings Per Share was $0.11 in the third quarter of 2016 as compared with $0.10 in the third quarter of 2015.

Also affecting Net Income in the third quarter of 2016 (excluding the items mentioned immediately above in the Adjusted Earnings Calculation) were certain non-cash expenses or non-recurring items including:  $1.2 million of non-cash employee stock compensation expense resulting from the vesting of certain options and restricted stock; $188,000 of severance paid in connection with headcount reductions related to cost savings initiatives; $66,000 gain on the sale of certain capital equipment; and $799,000 of amortization of deferred financing costs and loan discounts related to our credit facilities.

For the third quarter of 2016, as compared with the prior year’s third quarter, MRI volume increased 4.7%, CT volume increased 6.6% and PET/CT volume increased 9.0%.  Overall volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 6.7% over the prior year’s third quarter.  On a same-center basis, including only those centers which were part of RadNet for both the third quarters of 2016 and 2015, MRI volume increased 2.0%, CT volume increased 3.9% and PET/CT volume increased 6.3%.  Overall same-center volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 0.1% compared with the prior year’s same quarter.

Nine Month Financial Results

For the nine months ended September 30, 2016, RadNet reported Revenue of $659.6 million, Adjusted EBITDA⁽¹⁾ of $98.1 million and Net Income of $3.5 million.  Revenue increased $65.7 million (or 11.1%), Adjusted EBITDA⁽¹⁾ increased $9.0 million (or 10.1%) and Net Income decreased $3.3 million, respectively, over the first nine months of 2015.  Net Income Per Share for the nine month period ended September 30, 2016 was $0.08 per diluted share, compared to Net Income of $0.15 per diluted share in corresponding nine month period of 2015 (based upon a weighted average number of fully diluted shares outstanding of 46.7 million and 44.7 million for these periods in 2016 and 2015, respectively).

Affecting operating results in the nine months ended September 30, 2016 were certain non-cash expenses or non-recurring items including:  $4.9 million of non-cash employee stock compensation expense resulting from the vesting of certain options and restricted stock; $2.5 million of severance paid in connection with headcount reductions related to cost savings initiatives; $375,000 loss on the sale of certain capital equipment; $606,000 of one-time rating agency and legal fees related to our refinancing transaction completed on July 1, 2016; $5.0 million settlement gain related to the return of common stock in connection with our acquisition of Diagnostic Imaging Group; $6.1 million charge to Revenue related to working capital adjustments also pertaining to acquisitions we completed in New York; and $4.3 million of amortization of deferred financing costs and loan discounts related to our credit facilities.

2016 Guidance Update

RadNet reaffirms its previously announced 2016 guidance ranges as follows:

(a) Note the change from prior years.  This metric is now presented after the subtraction of bad debt.
(b) Net of proceeds from the sale of equipment, imaging centers and joint venture interests.  Represents an increase of $2 million from revised guidance range released in conjunction with our second quarter results.
(c) Defined by the Company as Adjusted EBITDA⁽¹⁾ less total capital expenditures and cash paid for interest.

Dr. Berger added, “We are on track to meet our guidance ranges for the year.  All ranges remain unchanged from what we announced previously with the exception of increasing and narrowing our targeted capital expenditure range by $3 million.  This increase is to continue to fund a replacement program of our computed radiography (CR x-ray) scanners to provide them with digital wireless transmitting capabilities as well as fund certain center expansions in several of our markets.”

Conference Call for Today

Dr. Howard Berger, President and Chief Executive Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call to discuss its third quarter 2016 results on Wednesday, November 9th, 2016 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

Conference Call Details:

Date:  Wednesday, November 9, 2016
Time:  10:30 a.m. Eastern Time
Dial In-Number:  888-417-8531
International Dial-In Number:  719-457-1517

It is recommended that participants dial in approximately 5 to 10 minutes prior to the start of the 10:30 a.m. call.  There will also be simultaneous and archived webcasts available at http://public.viavid.com/index.php?id=121830 or http://www.radnet.com under the “Investors” menu section and “News Releases” sub-menu of the website.  An archived replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international callers, and using the passcode 5168653.

Regulation G: GAAP and Non-GAAP Financial Information

This release contains certain financial information not reported in accordance with GAAP. The Company uses both GAAP and non-GAAP metrics to measure its financial results.  The Company believes that, in addition to GAAP metrics, these non-GAAP metrics assist the Company in measuring its cash-based performance.  The Company believes this information is useful to investors and other interested parties because it removes unusual and nonrecurring charges that occur in the affected period and provides a basis for measuring the Company's financial condition against other quarters.  Such information should not be considered as a substitute for any measures calculated in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies.  Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP.  Reconciliation of this information to the most comparable GAAP measures is included in this release in the tables which follow.

About RadNet, Inc.

RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 306 owned and/or operated outpatient imaging centers. RadNet's core markets include California, Maryland, Delaware, New Jersey, New York and Rhode Island. In addition, RadNet provides radiology information technology solutions, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry.  Together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, RadNet has a total of approximately 7,300 employees. For more information, visit http://www.radnet.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning successfully integrating acquired operations, successfully achieving 2016 financial guidance, achieving cost savings, successfully developing and integrating new lines of business, continuing to grow its business by generating patient referrals and contracts with radiology practices, and receiving third-party reimbursement for diagnostic imaging services, are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause the Company's actual results to differ materially from the statements contained herein. Further information on potential risk factors that could affect RadNet's business and its financial results are detailed in its most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. RadNet undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

Footnotes

⁽¹⁾ The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, each from continuing operations and adjusted for losses or gains on the sale of equipment, other income or loss, debt extinguishments and non-cash equity compensation.  Adjusted EBITDA includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling interests in subsidiaries, and is adjusted for non-cash or extraordinary and one-time events taken place during the period.

Adjusted EBITDA is reconciled to its nearest comparable GAAP financial measure.  Adjusted EBITDA is a non-GAAP financial measure used as analytical indicator by RadNet management and the healthcare industry to assess business performance, and is a measure of leverage capacity and ability to service debt.  Adjusted EBITDA should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.

⁽²⁾ As noted above, the Company defines Free Cash Flow as Adjusted EBITDA less total Capital Expenditures (whether completed with cash or financed) and Cash Interest paid.  Free Cash Flow is a non-GAAP financial measure.  The Company uses Free Cash Flow because the Company believes it provides useful information for investors and management because it measures our capacity to generate cash from our operating activities. Free Cash Flow does not represent total cash flow since it does not include the cash flows generated by or used in financing activities. In addition, our definition of Free Cash Flow may differ from definitions used by other companies.

Free Cash Flow should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.

CONTACTS:

RadNet, Inc.
Mark Stolper, 310-445-2800
Executive Vice President and Chief Financial Officer